Teduglutide, a glucagon-like peptide 2 agonist (GLP2), has been used in the treatment of patients suffering from SBS with chronic intestinal failure (SBS-CIF) requiring PS, including patients with CD and CIF (CD-CIF). This evidence concerns the gene GCG and macrothrombocytopenia and granulocyte inclusions with or without nephritis or sensorineural hearing loss.